The identification of a new drug target, such as an enzyme associated to a disease process, is often the initial step in the discovery and development of first-in-class drugs. Once a new target has been found, several strategies are employed to validate the target and support decisions, such as launching a large-scale drug development programme, conducting a proof-of-concept trial in humans, or collaborating with another company. Inadequate early-stage validation of therapeutic targets has been linked to costly clinical failures1 and low medication approval rates. The use of genomics to inform drug discovery and development pipelines has sparked both excitement and skepticism during the last three decades. Target validation can be characterized in a variety of ways depending on context, but it usually refers to a technical assessment of whether a target plays a crucial part in a disease process and whether pharmacological modulation of the target is efficacious in a given patient population.
Title : The role of ATP as a Hydrotrope in health and disease
Jack V Greiner, Harvard Medical School, United States
Title : Precision treatment of alzheimer's
Boris Tankhilevich, Magtera, Inc., United States
Title : Modeling competition between subpopulations with variable DNA content in resource limited microenvironments
Noemi Andor, H. Lee Moffitt Cancer Center & Research Institute, United States
Title : Progesterone receptor pathways in preterm birth
Beverlee Wood, Case Western Reserve University, United States
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Monitoring folds localization in ultra-thin transition metal dichalcogenides using Optical Harmonic Generation
Ahmed Raza Khan, Australian National University, Australia